# Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT05388006** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 27 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Richter Syndrome
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Acalabrutinib
- **BIOLOGICAL:** Durvalumab
- **DRUG:** Venetoclax
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Positron Emission Tomography (PET)
- **PROCEDURE:** Computed Tomography

## Key facts

- **NCT ID:** NCT05388006
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-05
- **Primary completion:** 2027-02-22
- **Final completion:** 2027-02-22
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05388006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05388006, "Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05388006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*